Nuvation Bio Investor Presentation March 2023 | Oncology Pipeline

Nuvation Bio presents its pipeline of wholly-owned oncology candidates targeting unmet needs in advanced solid tumors, including NUV-868 (BET inhibitor) in Phase 1 dose escalation and a Drug-Drug Conjugate platform. The company outlines anticipated milestones including IND filing submissions by year-end 2023 and ongoing combination studies with established oncology therapies.